Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Affector Medtech
Turku, Finland
- Ownership
- Private
- Development stage
- Other
01
Overview
Affector is a Finnish biotechnology company specializing in the development of small molecule inhibitors for transcription factors that are traditionally considered "undruggable." The company's primary focus is on targeting the STAT family of proteins, specifically STAT3 and STAT5, which are key drivers in various cancers and inflammatory diseases. By utilizing a proprietary screening platform, Affector aims to provide precision medicine solutions for patients with hematological malignancies and solid tumors. The company is a spin-off from the University of Turku and Åbo Akademi University and is headquartered in Turku, Finland.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Affector Medtech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Affector Medtech.